PubMed Health⌕ Search

PubMed · 7987642

p53 and human cancers.

Abstract

Mutations in the p53 gene are one of the commonest specific genetic changes found in human cancer. The p53 gene is not required for normal development but lack of p53 function confers an enormously elevated risk of developing cancer, thus it seems truly to act as a tumour suppressor gene. The p53 protein is normally present in minute amounts in cells but when cells are exposed to genotoxic stimuli p53 levels rise rapidly and initiate a programme of cell death, probably by means of transcriptional regulation. This response is lost in many tumour cells as they have either inactivated their p53 genes by mutation or blocked the activity of p53 through the production of proteins that bind to it and neutralise it. Mutant p53 proteins accumulate to high levels in many cancer cells and the p53 protein and the p53 response to DNA damage represent key points for therapeutic intervention.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

D P Lane. 1994. p53 and human cancers.. https://doi.org/10.1093/oxfordjournals.bmb.a072911

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

The role of Shp2 (PTPN11) in cancer.

Tyrosyl phosphorylation, which is controlled by protein-tyrosine kinases (PTKs) and protein-tyrosine phosphatases (PTPs), regulates numerous cellular processes. Altered expression and/or mutations in PTKs are linked to many forms of cancer, yet until recently little was known about the roles of PTPs in normal cells or in cancer. Earlier work established that a member of the PTP superfamily, PTEN, is an important tumor suppressor gene. We now know that at least one other PTP, the SH2 domain-containing phosphatase Shp2, is a bona fide oncogene that is mutated in several types of leukemia and hyperactivated by other mechanisms in some solid tumors. Understanding how Shp2 and other PTPs contribute to oncogenesis should provide new insights into pathogenesis and might suggest new targets for anti-neoplastic drugs.

Gene Expression Regulation, Neoplastic↗

Jak2: normal function and role in hematopoietic disorders.

Janus kinase 2 (Jak2) associates with cytokine receptors and is essential for signal transduction by mediating tyrosine phosphorylation. Kinase activity is regulated by a series of interactions beginning with the requirement to bind to specific domains in receptors, suppression of activation by the pseudokinase domain, and the requirement for phosphorylation within the activation loop. Recent studies have implicated de-regulation of Jak2 kinase activity by chromosomal translocations in hematopoietic tumors and mutations within the pseudokinase domain in a spectrum of myeloproliferative diseases.

Gene Expression Regulation, Neoplastic↗

Transcription factors in hematopoietic malignancies.

Transcription factors comprise a high proportion of the proteins with dysregulated expression or altered activity in cancer cells. In recent years, great progress has been made in elucidating crucial pathways in leukemogenesis, partially by identifying key transcription factors that are normally indispensable for hematopoiesis but which are often associated with malignant transformation when functioning improperly. The significance of transcription factors is highlighted by the multiple mechanisms used by leukemic cells to abrogate their normal activity. Delineating these mechanisms can benefit the diagnosis and treatment of hematological malignancies and might also be applicable to certain solid tumors.

Gene Expression Regulation, Neoplastic↗